[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":612},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,98,0,25,[9,46,74,96,126,147,170,193,217,241,272,291,310,337,366,389,410,435,456,481,505,524,542,562,588],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100644838","phase-4-efficacy-and-safety-of-fluticasone-propionate-nebulized-suspension-for-wheezing-diseases-in-infants-aged-0-24-months-100644838",false,"NCT07675252","Efficacy and Safety of Fluticasone Propionate Nebulized Suspension for Wheezing Diseases in Infants Aged 0-24 Months","A Multicenter Clinical Study on Efficacy and Safety of Fluticasone Propionate Nebulized Suspension in the Treatment of Wheezing Diseases in Infants Aged 0-24 Months","FPNS-IWD","Inclusion Criteria:\n\n* Age: 0-24 months, gender unlimited;\n* Clinical diagnosis: infantile wheezing, with the diagnostic criteria referring to Zhu Futang Practical Pediatrics (9th Edition);\n* Inpatients with acute clinical manifestations including wheezing, cough, sputum, and bilateral lung wheezes (wheezing and wheezes are mandatory), and the total score of wheezing symptoms and signs (including wheezing + wheezes) ≥ 2 points;\n* The onset of the above wheezing symptoms is within 72 hours;\n* The guardian of the subject consents and signs the informed consent form.\n\nExclusion Criteria:\n\n* Children with a clear diagnosis of congenital heart disease (excluding patent ductus arteriosus or patent foramen ovale), primary immunodeficiency, bronchopulmonary dysplasia, bronchiectasis, foreign bodies in the bronchi, pulmonary tuberculosis, or other congenital malformations that may cause wheezing diseases;\n* Those with comorbid primary diseases of the circulatory system, digestive system, urinary system, endocrine system, hematopoietic system, and immune system;\n* Those with severe respiratory insufficiency;\n* Those allergic to the study drugs;\n* Those who have received systemic hormone therapy during the current episode of the disease are not eligible for enrollment;\n* Before enrollment, any one of the laboratory test indicators meets the following criteria: Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) \\> 2 times the Upper Limit of Normal (ULN) (refer to the normal reference range of laboratory tests in the participating research center); Serum Creatinine (Scr)\n\n  * the Upper Limit of Normal.\n* Those who have participated in other clinical trials within the past 90 days are not eligible for enrollment;\n* Those who the researcher deems unsuitable for participating in the clinical trial are not eligible for enrollment.","ALL","0 Months","24 Months",{"count":22,"type":23},240,"ESTIMATED","INTERVENTIONAL",[26],"PHASE4","This study looks at how well and how safe fluticasone propionate nebulized suspension works in babies aged 0 to 24 months who have acute wheezing.\n\nInvestigators will compare it to budesonide nebulized suspension, another approved inhaled steroid.\n\nAbout 240 babies will join. Participants will be put into two groups by chance (1:1 randomization):\n\nOne group gets fluticasone propionate 0.5 mg twice a day by nebulizer The other group gets budesonide 1 mg twice a day by nebulizer Treatment lasts 5 to 7 days. Investigators will check breathing symptoms (wheezing, cough, phlegm, wheeze sounds in lungs) every day during treatment.\n\nThe study will check if fluticasone works as well as budesonide (non-inferiority) and may also check if it works better. Safety will be watched closely, including side effects, general health, and lab tests.\n\nThis study will help doctors know if fluticasone propionate nebulized suspension is a good treatment option for young babies with wheezing.",[29],"Acute Wheezing Disorders in Infants Aged 0 to 24 Months",[31,32,33],"FPN","Wheezing Disorders in Infants","0 - 24 months","NOT_YET_RECRUITING","2026-06-25",{"date":37,"type":38},"2026-06-30","ACTUAL",{"date":40,"type":23},"2026-08-01",{"date":42,"type":23},"2027-06-30",{"name":44,"class":45},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","OTHER",{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":24,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100644382","effectiveness-of-perioperative-percutaneous-acupuncture-on-postoperative-sleep-disturbances-and-chronic-pain-in-patients-undergoing-video-assisted-thoracoscopic-lung-cancer-resection-a-prospective-randomized-single-blind-superiority-controlled-trial-100644382","NCT07662733","Effectiveness of Perioperative Percutaneous Acupuncture on Postoperative Sleep Disturbances and Chronic Pain in Patients Undergoing Video-Assisted Thoracoscopic Lung Cancer Resection: A Prospective, Randomized, Single-Blind, Superiority Controlled Trial","Effectiveness of Perioperative Percutaneous Acupoint Acupuncture on Postoperative Sleep Disturbances in Patients Undergoing Video-Assisted Thoracoscopic Lung Cancer Resection: A Prospective, Randomized, Single-Blind, Superiority Controlled Trial","PASA-VATS","Inclusion Criteria：\n\n1. Patients aged 18-75 years scheduled for elective video-assisted thoracoscopic surgery (VATS) for lung cancer resection.\n2. American Society of Anesthesiologists (ASA) physical status classification I-II.\n3. Body Mass Index (BMI) between 18.5 and 28 kg\u002Fm².\n4. Clinical tumor stage according to the 8th edition of the AJCC\u002FUICC TNM Classification: cTis-3N0-1M0.\n5. Mentally competent, able to understand and correctly use the Numeric Rating Scale (NRS) for pain assessment.\n6. Willing and able to provide written informed consent prior to study participation.\n\nExclusion Criteria：\n\n1. Critical preoperative condition or inability to cooperate.\n2. History of sleep apnea or moderate to severe snoring.\n3. Pittsburgh Sleep Quality Index (PSQI) ≥7 or Athens Insomnia Scale (AIS) score ≥6.\n4. Implanted cardiac pacemaker, preoperative sinus bradycardia (heart rate ≤50 bpm), sinoatrial node disease, or second-\u002Fthird-degree atrioventricular block.\n5. Long-term use of anticonvulsants, antidepressants, or other psychotropic medications.\n6. Known hypersensitivity or allergy to the study materials (needles\u002Fdevices) or related medications.\n7. Severe cardiac, hepatic, or renal dysfunction.\n8. Participation in another clinical trial within the past 3 months.\n9. Hearing and\u002For language communication impairment.\n10. Pregnancy or breastfeeding.\n11. Fever (body temperature ≥38.5°C) or clinical evidence of infection (hematological, radiological, and\u002For microbiological) prior to surgery.\n12. Planned reoperation, or anticipated postoperative recurrence, severe complications, or critical illness requiring exclusion from follow-up.","18 Years","75 Years",{"count":57,"type":23},316,[59],"NA","This study evaluates whether acupuncture at specific body points before and after surgery can improve sleep quality and reduce long-term postoperative pain in patients undergoing video-assisted thoracoscopic lung cancer resection. Eligible adult patients will be randomly assigned to receive either true acupuncture or sham (placebo) acupuncture in addition to standard care. Chronic pain will be assessed during hospital stay and up to 6 months after surgery.",[62,63],"Postoperative Sleep Disturbances","Chronic Post-surgical Pain","RECRUITING","2026-06-17",{"date":67,"type":38},"2026-06-23",{"date":69,"type":38},"2025-06-13",{"date":71,"type":23},"2027-11-29",{"name":44,"class":45},2,{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":55,"enrollmentInfo":82,"targetDuration":4,"studyType":24,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":4},"100643671","phase-4-tegileridine-vs-sufentanil-for-postoperative-pain-management-and-gastrointestinal-recovery-after-major-laparoscopic-abdominal-surgery-100643671","NCT07637968","Tegileridine vs Sufentanil for Postoperative Pain Management and Gastrointestinal Recovery After Major Laparoscopic Abdominal Surgery","Tegileridine Versus Sufentanil for Postoperative Analgesia and Gastrointestinal Tolerability After Major Laparoscopic Abdominal Surgery: A Single-Center, Randomized, Triple-Blind Trial","TASPER","Inclusion Criteria:\n\n* Age 18-75 years.\n* Elective major abdominal surgery as defined above.\n* Body mass index (BMI) 18-30 kg\u002Fm².\n* American Society of Anesthesiologists (ASA) physical status I to III.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Known hypersensitivity to opioids or any component of the study medications.\n* Clinically significant hypoxemia, such as oxygen saturation less than 90 percentage, or a history of severe asthma.\n* Known or suspected gastrointestinal obstruction, including paralytic ileus.\n* Pregnancy or breastfeeding.\n* Severe hepatic impairment (Child-Pugh class C).\n* Severe heart failure (NYHA class III-IV) or unstable arrhythmia.\n* Neurological or psychiatric disorders that may interfere with pain or sedation assessment (e.g., epilepsy, impaired consciousness, uncontrolled psychiatric illness).\n* History of chronic pain or long-term use of analgesics\u002Fanalgesic products.\n* Current use of sedative-hypnotic medications.",{"count":83,"type":23},84,[26],"This study is a single-center, randomized, triple-blind clinical trial designed to compare tegileridine and sufentanil for postoperative analgesia and gastrointestinal tolerability in patients undergoing major laparoscopic abdominal surgery. Participants will be randomly assigned to receive either tegileridine or sufentanil for postoperative patient-controlled intravenous analgesia according to the study protocol. The purpose of this study is to determine whether tegileridine can provide better gastrointestinal tolerability while maintaining non-inferior postoperative pain control compared with sufentanil in this patient population.",[87],"Postoperative Pain","2026-06-04",{"date":90,"type":38},"2026-06-10",{"date":92,"type":23},"2026-06-01",{"date":94,"type":23},"2027-06-01",{"name":44,"class":45},{"id":97,"slug":98,"hasResults":12,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":12,"sex":18,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":24,"phases":108,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},"100638604","subthalamic-nucleus-targeted-transcranial-temporal-interference-stimulation-for-motor-and-non-motor-symptoms-in-parkinsons-disease-100638604","NCT07625540","Subthalamic Nucleus-Targeted Transcranial Temporal Interference Stimulation for Motor and Non-Motor Symptoms in Parkinson's Disease","Study on the Efficacy and Safety of Subthalamic Nucleus (STN)-Targeted Transcranial Temporal Interference Stimulation (tTIS) for Motor and Non-Motor Symptoms in Parkinson's Disease (PD): A Randomized, Double-Blind, Controlled Exploratory Trial","STN-tTIS-PD","Inclusion Criteria:\n\n* Aged 50-85 years, male or female.\n* Diagnosed with \"clinically established\" or \"clinically probable\" Parkinson's disease according to the 2015 MDS Clinical Diagnostic Criteria for Parkinson's Disease.\n* Hoehn-Yahr stage ≥ 2, and judged by the investigator to be able to cooperate in completing scale-based assessments and MRI examinations.\n* Stable regimen of anti-Parkinsonian medication for at least 4 weeks before enrollment, and agreement to maintain a stable regimen during the main study phase unless medically necessary to change.\n* Written informed consent signed by the study participant.\n\nExclusion Criteria:\n\n* Non-primary Parkinson's disease or other parkinsonism \u002F atypical parkinsonism.\n* Previous receipt of invasive neuromodulation therapies such as deep brain stimulation (DBS) or other intracranial implantation\u002Fstereotactic brain surgery.\n* Presence of contraindications or high-risk conditions for transcranial electrical stimulation (e.g., incompatible metal implants\u002Fimplantable electrical stimulation devices, etc.), or judged by the investigator as unsuitable to receive transcranial electrical stimulation.\n* Receipt of non-invasive neuromodulation interventions such as transcranial magnetic stimulation or transcranial electrical stimulation within the past six months.\n* Presence of contraindications to MRI or inability to tolerate MRI examination.\n* Significant cognitive impairment or severe psychiatric symptoms that prevent completion of assessments or result in poor compliance.\n* New initiation or dose adjustment of medications or treatments that significantly affect sleep architecture\u002Fconsciousness status within the past 4 weeks.\n* History of epilepsy.\n* Pregnancy or breastfeeding.\n* Any other condition judged by the investigator as unsuitable for participation in the study.","50 Years","85 Years",{"count":107,"type":23},32,[59],"Transcranial temporal interference stimulation (tTIS) is a non-invasive deep brain stimulation method. This study aims to comprehensively explore the efficacy and safety of bilateral subthalamic nucleus (STN) tTIS on motor and non-motor symptoms in patients with Parkinson's disease (PD).",[111],"Parkinson's Disease (PD)",[113,114,115,116,117],"Parkinson's disease","transcranial Temporal Interference Stimulation","subthalamic nucleus","motor symptoms","non-motor symptoms","2026-06-02",{"date":88,"type":38},{"date":121,"type":38},"2026-05-20",{"date":123,"type":23},"2027-04",{"name":44,"class":45},1,{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":24,"phases":135,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":125},"100626706","early-phase-1-safety-and-tolerability-study-of-68ga177lu-brp-020063-in-advanced-solid-tumors-100626706","NCT07439120","Safety and Tolerability Study of 68Ga\u002F177Lu-BRP-020063 in Advanced Solid Tumors","A Study Evaluating the Safety, Pharmacokinetics, and Radiation Dosimetry of 68Ga\u002F177Lu-BRP-020063 in Patients With Advanced Metastatic Solid Tumors.","Inclusion Criteria:\n\n1. Age ≥ 18 years, regardless of gender;\n2. Patients with a confirmed diagnosis of advanced metastatic solid tumor (preferably urothelial carcinoma, followed by breast cancer);\n3. Willing to provide archived or freshly biopsied tumor tissue specimens (recommended within the past 2 years);\n4. Performance status (ECOG) score of 0-1;\n5. Adequate organ function:\n\n   * Complete Blood Count: White blood cell count ≥ 3.0 × 10⁹\u002FL, neutrophil count ≥ 1.5 × 10⁹\u002FL, hemoglobin ≥ 90 g\u002FL, platelet count ≥ 75 × 10⁹\u002FL;\n   * Liver function: Total bilirubin ≤ 2.5 × ULN, alanine aminotransferase ≤ 3 × ULN, aspartate aminotransferase ≤ 3 × ULN;\n   * Renal function: Creatinine clearance ≥ 50 mL\u002Fmin (Cockcroft-Gault formula);\n   * Coagulation function: Prothrombin time ≤ 1.5 × ULN, activated partial thromboplastin time ≤ 1.5 × ULN, international normalized ratio ≤ 1.5 × ULN;\n6. Subjects of childbearing potential must voluntarily adopt effective contraception during the treatment period and for 6 months after the last dose of the investigational drug (for females);\n7. Willing to participate in this trial and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Previous treatment with Nectin-4-targeted drugs (including clinical trials);\n2. Inability to complete PET\u002FCT or SPECT\u002FCT examinations (including inability to lie flat, claustrophobia, radiophobia, etc.);\n3. Participation in drug or device clinical studies within 4 weeks prior to the first dose;\n4. Presence of severe or uncontrolled underlying diseases, including but not limited to:\n\n   1. NYHA Class II or higher congestive heart failure, or severe arrhythmia requiring medication;\n   2. Severe cardiovascular\u002Fcerebrovascular or valvular diseases;\n   3. Poorly controlled diabetes or hypertension;\n5. Inability to tolerate intravenous administration or difficulty with venipuncture (e.g., history of needle or blood phobia);\n6. Active infection within 4 weeks prior to the first dose;\n7. Women who are planning pregnancy, currently pregnant, or breastfeeding;\n8. Allergy to radioactive rays or other severe allergic history;\n9. History of neurological metastasis with associated symptoms;\n10. Concurrent other malignancies;\n11. Undergone general anesthesia surgery within 4 weeks prior to the first dose;\n12. Other conditions deemed by the investigator as unsuitable for inclusion in the clinical study.",{"count":134,"type":23},10,[136],"EARLY_PHASE1","This study is an open-label, single-arm, interventional clinical trial designed to investigate the safety of ⁶⁸Ga\u002F¹⁷⁷Lu-BRP-020063 in patients with advanced metastatic solid tumors; to evaluate the pharmacokinetics, biodistribution, and radiation dosimetry of ¹⁷⁷Lu-BRP-020063 in patients with metastatic solid tumors; and to preliminarily explore its therapeutic efficacy. The study plans to enroll 10 patients to receive ⁶⁸Ga-BRP-020063 PET\u002FCT imaging, among whom 5 patients positive for ⁶⁸Ga-BRP-020063 will be selected to receive a low dose of ¹⁷⁷Lu-BRP-020063. The results of this study will provide a basis for the design of subsequent studies involving higher doses of ¹⁷⁷Lu-BRP-020063.",[139],"Urothelial Carcinoma (UC)",{"date":141,"type":38},"2026-06-03",{"date":143,"type":38},"2026-04-13",{"date":145,"type":23},"2026-08-31",{"name":44,"class":45},{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":12,"sex":18,"minAge":155,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":24,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":166,"completionDateStruct":167,"leadSponsor":169,"locationsCount":4},"100637895","vr-for-cataract-anxiety-lowering-management--a-rct-study-100637895","NCT07620821","VR for Cataract Anxiety Lowering Management--A RCT Study","A Randomized Controlled Study of Virtual Reality Simulation of Intraoperative Audiovisual Experience to Reduce Anxiety in Cataract Surgery Patients","VR-CALM","Inclusion Criteria:\n\n1. Diagnosed with cataracts in one or both eyes, and planning to undergo surgical treatment\n2. Voluntarily participate in this trial and sign the informed consent form.\n\nExclusion Criteria:\n\n1. History of previous ophthalmic surgery\n2. Suffering from severe hearing impairment, unable to comprehend VR video content.\n3. Those who suffer from cognitive dysfunction or mental illness and are unable to cooperate in completing the scale assessment.\n4. Suffering from severe macular diseases, glaucoma, or other ocular diseases that may affect surgery or interfere with the assessment of tension level.\n5. Assessed as intolerant to topical anesthesia for the surgery.\n6. History of motion sickness, severe vertigo, or intolerance to VR video viewing (such as claustrophobia).\n7. Other situations where the researcher deems the participant unsuitable for participation in this study.","20 Years","90 Years",{"count":158,"type":23},260,[59],"Cataract is currently the leading cause of blindness globally, and surgery is the only effective treatment. With the advancement of medical technology, cataract surgery is usually performed under topical anesthesia, which means patients will be awake during the procedure, able to see the light from the surgical lamp and hear the sounds of surgical instruments being operated. Some patients may feel nervous or scared due to unfamiliarity with the surgical process, which may lead to increased blood pressure, rapid heartbeat, and even affect their cooperation during the surgery.Virtual reality (VR) technology is a new multimedia technology. By wearing VR glasses, patients can immerse themselves in a virtual world and see and hear realistic scenes. Through this study, the investigators aim to investigate whether allowing cataract patients to \"experience\" a surgical procedure in advance through VR glasses before cataract surgery can help alleviate their nervousness during the actual surgery.",[162,163],"Cataract and IOL Surgery","VR-based Informed Consent","2026-05-27",{"date":118,"type":38},{"date":92,"type":23},{"date":168,"type":23},"2026-09-30",{"name":44,"class":45},{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":12,"sex":18,"minAge":104,"maxAge":105,"enrollmentInfo":177,"targetDuration":4,"studyType":24,"phases":179,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":73},"100618219","ai-vs-physician-for-anti-vegf-decision-making-an-rct-100618219","NCT07328776","AI vs. Physician for Anti-VEGF Decision-Making: An RCT","An Artificial Intelligence System for Anti-VEGF Treatment Decisions in Retinal Diseases: A Randomized Controlled Trial","Inclusion Criteria:\n\nPatients with a diagnosis of nAMD, DME, and RVO; Patients who have completed the loading-dose treatment of anti-VEGF agents; Patients who were willing to participate and provided written informed consent.\n\nExclusion Criteria:\n\nRefusal to undergo OCT testing; Refusal to complete the 3-month follow-up period; Screening for a history of intraocular surgery within the past 6 months; Subjects with severe systemic diseases, intellectual developmental disorders, psychiatric illnesses, etc.",{"count":178,"type":23},200,[59],"We developed an artificial intelligence system, called QiLin, which was designed to assist anti-VEGF treatment decisions in retinal diseases. QiLin was trained and validated via over 20,000 optical coherence tomography images from multicenter datasets, demonstrating strong performance on both internal and external validation. To evaluate its real-world clinical utility, we conducted a randomized controlled trial that rigorously compares the accuracy of treatment decisions between a physician-only arm and an AI-assisted physician arm.",[182,183,184],"DME","Retinal Vein Occlusion (RVO)","Neovascular (Wet) Age-Related Macular Degeneration","2026-05-18",{"date":187,"type":38},"2026-05-22",{"date":189,"type":23},"2026-05-25",{"date":191,"type":23},"2026-10-15",{"name":44,"class":45},{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":200,"minAge":155,"maxAge":156,"enrollmentInfo":201,"targetDuration":4,"studyType":203,"phases":4,"briefSummary":204,"conditions":205,"keywords":208,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":125},"100640259","development-and-validation-of-a-risk-prediction-model-for-de-novo-stress-urinary-incontinence-after-pelvic-floor-reconstruction-surgery-100640259","NCT07601282","Development and Validation of a Risk Prediction Model for De Novo Stress Urinary Incontinence After Pelvic Floor Reconstruction Surgery","Development and Validation of a Risk Prediction Model for De Novo Stress Urinary Incontinence After Pelvic Floor Reconstruction Surgery: A Case-Control Study","Inclusion Criteria:\n\n1. Patients with pelvic organ prolapse quantification (POP-Q) stage II or higher;\n2. Patients who require surgical treatment for pelvic organ prolapse;\n3. Patients with no evidence of urinary incontinence before surgery.\n\nExclusion Criteria:\n\n1. Patients confirmed to have urinary incontinence before surgery;\n2. Patients with urinary or reproductive system infections;\n3. Patients with a history of prior surgery for urinary incontinence;\n4. Patients who have undergone previous mesh repair surgery for pelvic organ prolapse;\n5. Patients with a history of psychiatric disorders, hearing impairment, or communication difficulties;\n6. Patients receiving hormone replacement therapy;\n7. Patients with neurodegenerative diseases such as stroke or multiple sclerosis, or neurological conditions such as spinal cord injury.","FEMALE",{"count":202,"type":23},382,"OBSERVATIONAL","This observational study aims to develop a predictive model for the occurrence of new-onset stress urinary incontinence (SUI) after pelvic organ prolapse (POP) repair surgery in women. The primary questions it seeks to answer are:\n\nWhich risk factors and anatomical characteristics predispose women to new-onset stress urinary incontinence following pelvic organ prolapse repair surgery?\n\nFemale POP patients without any preoperative symptoms of urinary incontinence will receive telephone follow-ups at 3, 6, and 12 months after undergoing standard surgical treatment.",[206,207],"Pelvic Organ Prolapse (POP)","Stress Urinary Incontinence (SUI)",[209],"Case-Control Study","2026-05-16",{"date":187,"type":38},{"date":213,"type":38},"2024-12-01",{"date":215,"type":23},"2026-12-31",{"name":44,"class":45},{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":55,"enrollmentInfo":224,"targetDuration":4,"studyType":24,"phases":226,"briefSummary":228,"conditions":229,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":125},"100638524","phase-2-nimotuzumab-combined-with-pd-1-inhibitors-and-chemotherapy-in-the-treatment-of-locally-advanced-head-and-neck-squamous-cell-carcinoma-100638524","NCT07601737","Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma","A Prospective, Randomized, Phase II Study of Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma","Inclusion Criteria:\n\n1. Age 18 to 75 years inclusive.\n2. Histologically or cytologically confirmed squamous cell carcinoma of the head and neck (HNSCC) (oral cavity, oropharynx, larynx, hypopharynx), stage III-IVB per AJCC 8th edition.\n3. Resectable disease assessed by a multidisciplinary team (MDT) including surgical, radiological, and pathological specialists.\n4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n5. For oropharyngeal carcinoma: mandatory p16 immunohistochemistry (testing within standard of care is acceptable; repeat testing not required). p16 testing is not required for other tumor locations.\n6. Availability of tumor tissue (archived or newly obtained) for PD-L1 testing (prior testing is acceptable; repeat testing not required).\n7. At least one measurable lesion per RECIST 1.1.\n8. Life expectancy ≥ 6 months.\n9. Adequate hematologic function:\n\n   White blood cell count ≥ 4.0 × 10⁹\u002FL Absolute neutrophil count ≥ 1.5 × 10⁹\u002FL Platelet count ≥ 100 × 10⁹\u002FL Hemoglobin ≥ 90 g\u002FL\n10. Adequate renal function:\n\n    Serum creatinine ≤ 1.5 × upper limit of normal (ULN) OR\n\n    Creatinine clearance (CrCl) ≥ 60 mL\u002Fmin calculated by Cockcroft-Gault formula:\n\n    Female: CrCl (mL\u002Fmin) = (140 - age) × body weight (kg) × 0.85 \u002F (72 × serum creatinine (mg\u002FdL)) Male: CrCl (mL\u002Fmin) = (140 - age) × body weight (kg) × 1.00 \u002F (72 × serum creatinine (mg\u002FdL))\n11. Adequate hepatic function:\n\n    Total bilirubin ≤ 1.5 × ULN Aspartate aminotransferase (AST) ≤ 2.5 × ULN Alanine aminotransferase (ALT) ≤ 2.5 × ULN\n12. Female subjects: negative pregnancy test within 2 weeks before first study drug, non-lactating.\n\n    Females: highly effective contraception required during study and for 6 months after last study drug.\n\n    Males: highly effective contraception required during study and for 6 months after last study drug.\n13. Written informed consent obtained prior to any study-specific procedures, and willingness to comply with all study visits and protocol requirements.\n\nExclusion Criteria:\n\n1. Received PD-1 inhibitors, EGFR monoclonal antibodies, EGFR-TKIs, or anti-angiogenic agents within 4 weeks prior to enrollment.\n2. Participation in another interventional clinical trial within 30 days prior to screening.\n3. In the investigator's judgment, the patient cannot tolerate or has contraindications to platinum-based chemotherapy (cisplatin or carboplatin) as specified in the protocol.\n4. Unresectable disease, poor medical condition for surgery, refusal of surgery for any reason, or excessive tumor burden precluding resection.\n5. History of other malignancy within the past 5 years (except cured basal cell carcinoma of the skin).\n6. History of primary immunodeficiency disease.\n7. Presence of uncontrolled comorbidities, including heart failure, severe pulmonary disease, severe hepatic disease, psychiatric disorders, etc.\n8. Known HIV infection, active viral hepatitis, or active tuberculosis.\n9. Underwent major surgery within 90 days prior to the first study drug, or planning major surgery unrelated to this cancer treatment.\n10. Hypersensitivity to any study drug or their components.\n11. Pregnant (confirmed by serum or urine HCG test) or lactating woman; or subject of childbearing potential unwilling or unable to use effective contraception during study treatment and for at least 6 months after the last dose of study treatment (applicable to both males and females).\n12. Investigator considers the subject not suitable for study participation.\n13. Unwilling to participate or unable to provide written informed consent.\n14. Receipt of a live vaccine within 30 days before the first study drug administration.",{"count":225,"type":23},182,[227],"PHASE2","This is a randomized controlled, phase II clinical study designed to explore the efficacy and safety of nimotuzumab combined with immunotherapy and chemotherapy as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (LA-HNSCC). The primary endpoint of the study is the 2-year event-free survival (EFS) rate. Enrollment is expected to be completed within 2 years; all patients will be followed up for at least 2 years after the last patient is enrolled.",[230,231,232,233],"Head and Neck Squamous Cell Carcinoma","Head and Neck Squamous Cell Carcinoma (HNSCC)","Head & Neck Cancer","Neoadjuvant Therapy","2026-05-15",{"date":187,"type":38},{"date":237,"type":38},"2026-04-20",{"date":239,"type":23},"2030-04-30",{"name":44,"class":45},{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":249,"enrollmentInfo":250,"targetDuration":252,"studyType":203,"phases":4,"briefSummary":253,"conditions":254,"keywords":257,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":125},"100639234","correlation-of-eus-swq-and-liver-fibrosis-pathology-in-chronic-liver-disease-100639234","NCT07588854","Correlation Of EUS-SWQ And Liver Fibrosis Pathology In Chronic Liver Disease","EU-ME3 Endoscopic Ultrasound Shear Wave Quantification (EUS-SWQ) for Evaluating Liver Fibrosis and Histopathology in Patients With Chronic Liver Disease","EUS-SWQ-202601","Inclusion Criteria:\n\n1. Age ≥ 18 years and ≤ 80 years.\n2. Patients with clinical indications scheduled to undergo liver biopsy (EUS-guided) for the evaluation of liver lesions. Chronic liver disease meeting criteria for biopsy includes:Hepatitis B；Fatty liver disease；Autoimmune hepatitis；Other chronic liver diseases of unknown etiology that would benefit from liver biopsy\n3. Planned to undergo EUS-SWQ and FibroScan examinations prior to biopsy.\n4. Willing to provide and sign written informed consent.\n\nExclusion Criteria:\n\n1. Patients unable to tolerate endoscopic procedures.\n2. Patients with contraindications to endoscopy or anesthesia.\n3. Coagulopathy (platelet count \\\u003C 50×10⁹\u002FL, PT \\> upper limit of normal by 3 seconds).\n4. Patients with severe underlying diseases of the respiratory, cardiovascular, cerebrovascular, digestive, or hematologic systems, as well as those with psychiatric disorders.\n5. Patients with surgically altered anatomy that precludes adequate EUS imaging of the hepatic parenchyma.\n6. Patients with imaging findings suggestive of malignant liver tumors.\n7. Pregnant or lactating women.\n8. Patients with decompensated cirrhosis (gastrointestinal bleeding, ascites, encephalopathy).\n9. Patients who refuse to participate in the clinical study.\n10. Any other conditions deemed inappropriate by the investigator.","80 Years",{"count":251,"type":23},65,"2 Weeks","The goal of this clinical study is to learn whether the Olympus EU-ME3 endoscopic ultrasound shear wave quantification (EUS-SWQ) function can accurately diagnose and grade liver fibrosis in patients with chronic liver disease. It will also learn about the safety and measurement success rate of EUS-SWQ.\n\nThe main questions it aims to answer are:\n\nHow closely do EUS-SWQ measurements match liver fibrosis stages determined by liver biopsy (the reference standard)? Does EUS-SWQ correlate better with liver biopsy results than FibroScan? How safe is EUS-SWQ and how often can successful measurements be obtained? Researchers will compare EUS-SWQ results with liver biopsy pathology (METAVIR F0-F4) and with FibroScan results to evaluate its diagnostic value.\n\nParticipants will:\n\nBe adults with chronic liver disease who are scheduled to undergo a clinically indicated liver biopsy Undergo an EUS-SWQ examination as part of the study Have their liver stiffness measured by both EUS-SWQ and FibroScan for comparison Be monitored for any discomfort or adverse events related to the procedures A total of 65 participants will take part in this prospective, single-center, post-market clinical study.",[255,256],"Chronic Liver Disease (CLD)","Liver Fibrosis",[258,259,260,261,262,263,264],"Chronic liver disease","Liver fibrosis","EUS-SWQ","Endoscopic ultrasound","Liver biopsy","FibroScan","Olympus EU-ME3","2026-05-13",{"date":234,"type":38},{"date":268,"type":23},"2026-05",{"date":270,"type":23},"2028-01",{"name":44,"class":45},{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":153,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":18,"minAge":104,"maxAge":249,"enrollmentInfo":279,"targetDuration":4,"studyType":24,"phases":281,"briefSummary":282,"conditions":283,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":290,"locationsCount":4},"100640192","vr-for-cataract-anxiety-lowering-management-100640192","NCT07586280","VR for Cataract Anxiety Lowering Management","A Non-Randomized Controlled Trial of Virtual Reality Simulation of Intraoperative Audiovisual Experience to Reduce Anxiety in Cataract Surgery Patients","Inclusion Criteria:\n\n1. Diagnosed with cataracts in both eyes, and planning to undergo surgical treatment\n2. Voluntarily participate in this trial and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Having any history of previous ophthalmic surgery.\n2. Suffering from severe hearing impairment, unable to comprehend VR video content.\n3. Those who suffer from cognitive dysfunction or mental illness and are unable to cooperate in completing the scale assessment.\n4. Suffering from severe macular diseases, glaucoma, or other ocular diseases that may affect surgery or interfere with the assessment of tension level.\n5. Assessed as intolerant to surface anesthesia surgery.\n6. History of motion sickness, severe vertigo, or intolerance to VR video viewing (such as claustrophobia).\n7. Other situations where the researcher deems the participant unsuitable for participation in this study.",{"count":280,"type":23},60,[59],"Cataract is currently the leading cause of blindness globally, and surgery is the only effective treatment. With the advancement of medical technology, cataract surgery is usually performed under topical anesthesia, which means patients will be awake during the procedure, able to see the light from the surgical lamp and hear the sounds of surgical instruments being operated. Some patients may feel nervous or scared due to unfamiliarity with the surgical process, which may lead to increased blood pressure, rapid heartbeat, and even affect their cooperation during the surgery.\n\nVirtual reality (VR) technology is a new multimedia technology. By wearing VR glasses, patients can immerse themselves in a virtual world and see and hear realistic scenes. Through this study, the investigators aim to investigate whether allowing cataract patients to \"experience\" a surgical procedure in advance through VR glasses before cataract surgery can help alleviate their nervousness during the actual surgery.",[163,162],"2026-05-12",{"date":286,"type":38},"2026-05-14",{"date":288,"type":23},"2026-05-01",{"date":168,"type":23},{"name":44,"class":45},{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":18,"minAge":297,"maxAge":298,"enrollmentInfo":299,"targetDuration":20,"studyType":203,"phases":4,"briefSummary":300,"conditions":301,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":4},"100638295","autologous-versus-allogeneic-hematopoietic-stem-cell-transplantation-for-t-lymphoblastic-leukemialymphoma-in-first-complete-remission-100638295","NCT07577531","Autologous Versus Allogeneic Hematopoietic Stem Cell Transplantation for T-Lymphoblastic Leukemia\u002FLymphoma in First Complete Remission","* Inclusion Criteria:\n* Age 14-55 years, no gender restriction\n* Expected survival \\>12 weeks\n* ECOG performance status 0-2\n* Pathologically or by bone marrow flow cytometry confirmed •T-lymphoblastic lymphoma in first complete remission (CR1) after chemotherapy; CR1 criteria: first complete remission, defined as: ① For intramedullary disease, meeting the CR criteria of the 2024 Chinese Adult Acute Lymphblastic Leukemia Diagnosis and Treatment Guidelines (2024 edition) with flow cytometric\u002Fgene testing showing MRD negativity; ② For extramedullary disease, meeting the Lugano 2014 response criteria for CR with a PET-CT score of 1-2\n* Hepatic, renal, cardiac, and pulmonary function meeting the following requirements:\n\n  1. Creatinine clearance (by Cockcroft-Gault formula) ≥60 mL\u002Fmin\n  2. Cardiac ejection fraction \\>50%, with no clinically significant ECG abnormalities\n  3. Baseline oxygen saturation \\>92%\n  4. Total bilirubin ≤1.5×ULN; ALT and AST ≤3×ULN\n* Ability to understand the trial and signed informed consent\n* Exclusion Criteria:\n* Malignancies other than acute T-lymphoblastic leukemia, T-cell lymphoma, or T-lymphoblastic lymphoma within 5 years prior to screening, except for adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical surgery, ductal carcinoma in situ after radical surgery, or thyroid cancer after radical surgery.\n* Active, uncontrolled bacterial, viral, or fungal diseases requiring treatment; HBsAg or HBcAb positive with peripheral blood HBV DNA ≥ lower limit of detection; HCV antibody positive with peripheral blood HCV RNA positive; positive TRUST test for syphilis; positive HIV antibody.\n* Dysfunction of vital organs (cardiovascular, cerebrovascular, pulmonary);history of active gastrointestinal bleeding within the past 3 months; uncontrolled hypertension or history of hypertensive crisis or hypertensive encephalopathy; history or evidence of major cardiovascular risk, including any of the following: congestive heart failure, unstable angina, clinically significant arrhythmias (e.g., ventricular fibrillation, ventricular tachycardia); history of arterial thrombosis within the past 3 months (e.g., stroke, transient ischemic attack); history of symptomatic deep vein thrombosis or pulmonary embolism within the past 6 months, or history of coronary angioplasty, defibrillation, or any clinically relevant complication or disease that may pose a risk to subject safety or interfere with study assessments, procedures, or completion.\n* Any other uncontrolled active disease that precludes participation in the trial.\n* Active, uncontrolled central nervous system involvement, or subjects with a history of CNS disease requiring treatment (e.g., epilepsy patients).\n* Pregnant or breastfeeding women; subjects planning to become pregnant within 1 year after infusion, or during or after treatment.\n* Presence of uncontrolled active infection (excluding simple urinary tract infection or upper respiratory tract infection).\n* Known allergy to conditioning regimen drugs.\n* Any condition that, in the investigator's judgment, would compromise subject safety or interfere with study objectives, or subjects deemed unsuitable for participation in this trial; subjects with illnesses affecting their ability to give written informed consent or to comply with study procedures; unwilling or unable to comply with study requirements","14 Years","55 Years",{"count":83,"type":23},"To evaluate, through a prospective multicenter observational study, autologous or allogeneic hematopoietic stem cell transplantation (Auto-SCT\u002Fallo-SCT)as consolidation therapy in subjects with T lymphoblastic leukemia\u002FLymphoblastic lymphoma(T-ALL\u002FLBL)who have achieved first complete remission (CR). Assess relapse-free survival (RFS), overall survival (OS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM) among different treatment regimens",[302],"T Cell Acute Lymphoblastic Leukemia\u002FLymphoblastic Lymphoma","2026-05-10",{"date":265,"type":38},{"date":306,"type":23},"2026-05-05",{"date":308,"type":23},"2029-05-05",{"name":44,"class":45},{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":318,"enrollmentInfo":319,"targetDuration":4,"studyType":24,"phases":321,"briefSummary":322,"conditions":323,"keywords":326,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":334,"leadSponsor":336,"locationsCount":125},"100636827","phase-2-low-dose-atgptcy-plus-ivarmacitinib-for-agvhd-prevention-in-haplo-pbsct-from-parous-female-donors-100636827","NCT07570745","Low-Dose ATG\u002FPTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors","Low-Dose ATG\u002FPTCy Plus Ivarmacitinib to Prevent Acute Graft-versus-Host Disease Following Haploidentical Peripheral Blood Stem Cell Transplantation From Parous Female Donors: A Prospective, Single-Arm, Multicenter Trial","PARITY","Inclusion Criteria:\n\n1. Age 18-70 years, any gender. Recipients must be diagnosed with hematologic malignancies, such as acute leukemia, myelodysplastic syndrome, or malignant lymphoma, and are planned to undergo haploidentical peripheral blood stem cell transplantation (Haplo-PBSCT).\n2. The donor must be a haploidentical relative within three degrees of kinship and a parous female (having given birth; number of pregnancies not limited), aged 18-55 years, in good health, and cleared by donor screening.\n3. Karnofsky performance status ≥70. The recipient is expected to tolerate transplant-related toxicity. Major organ functions must meet transplantation requirements: cardiac and pulmonary function essentially normal; liver function: ALT\u002FAST \\\u003C2× upper limit of normal, total bilirubin \\\u003C1.5× upper limit of normal; renal function: creatinine clearance \\>50 mL\u002Fmin.\n4. No active infection prior to transplantation (or infection effectively controlled). Chronic infections such as HBV, HCV, or syphilis must be stable under treatment; HBV DNA negative or receiving antiviral therapy is acceptable.\n5. No significant psychiatric disorders; able to understand and voluntarily consent to participate in the study.\n6. The patient has signed the informed consent form and agrees to comply with follow-up and related examinations.\n\nExclusion Criteria:\n\n1. History of prior hematopoietic stem cell transplantation (including autologous or allogeneic transplant).\n2. Presence of donor-specific antibodies (DSA) with a mean fluorescence intensity (MFI) ≥5000.\n3. History of severe hypersensitivity or allergy to JAK inhibitors or the investigational drug.\n4. Prior treatment with JAK1\u002F2 inhibitors.\n5. Uncontrolled comorbidities prior to transplantation, such as uncontrolled hypertension, diabetes complications, or active gastrointestinal ulcer bleeding, which may increase unacceptable risk for trial participation as evaluated by investigators.\n6. Receipt of other investigational drugs within 2 weeks prior to transplantation (excluding standard chemotherapy), or simultaneous participation in other interventional clinical studies, or any other condition deemed by the investigator to make the patient unsuitable for study participation, including poor compliance or inability to complete follow-up (e.g., severe psychiatric disorders preventing cooperation).","70 Years",{"count":320,"type":23},82,[227],"Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), significantly affecting survival and quality of life. Acute GVHD (aGVHD) typically occurs within 100 days post-transplant, commonly involving skin, gastrointestinal tract, and liver. Chronic GVHD (cGVHD) can appear months to years later.\n\nDespite prophylaxis with calcineurin inhibitors (e.g., cyclosporine or tacrolimus), methotrexate, mycophenolate mofetil, and post-transplant cyclophosphamide (PTCy), patients receiving haploidentical transplantation from parous female donors remain at high risk for moderate-to-severe aGVHD.\n\nJAK1-dependent cytokine signaling (IL-6, IFN-γ) is central to GVHD pathogenesis. Selective JAK1 inhibition may attenuate T cell-mediated inflammation while preserving hematopoiesis. Ivarmacitinib (SHR0302) is a highly selective oral JAK1 inhibitor, showing favorable safety and preliminary efficacy in autoimmune and GVHD settings, making it a candidate for early GVHD prophylaxis.",[324,325],"Graft-Versus-Host Disease(GVHD)","Bone Marrow Transplantation",[327,328,329,330],"Graft-versus-host disease","Haploidentical transplantation","Low-dose ATG\u002FPTCy","JAK1 inhibitor (Ivarmacitinib \u002F SHR0302)",{"date":332,"type":38},"2026-05-06",{"date":288,"type":23},{"date":335,"type":23},"2029-05-01",{"name":44,"class":45},{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":343,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":18,"minAge":298,"maxAge":55,"enrollmentInfo":345,"targetDuration":4,"studyType":24,"phases":347,"briefSummary":348,"conditions":349,"keywords":351,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":4},"100636302","tbf-conditioning-regimen-for-haploidentical-stem-cell-transplantation-in-elderly-aml-patients-in-first-complete-remission-100636302","NCT07563920","TBF Conditioning Regimen for Haploidentical Stem Cell Transplantation in Elderly AML Patients in First Complete Remission","A Single-Center, Prospective, Single-Arm Clinical Study Evaluating the Efficacy and Safety of Thiotepa, Busulfan, and Fludarabine (TBF) Conditioning Regimen in Haploidentical Peripheral Blood Stem Cell Transplantation for Elderly Acute Myeloid Leukemia Patients in First Complete Remission","TBF-AML","Inclusion Criteria:\n\n* Age 55 to 75 years\n* Diagnosed with acute myeloid leukemia (AML) based on morphology, immunophenotyping, cytogenetics, or molecular testing\n* First complete remission (CR1) or complete remission with incomplete hematologic recovery (CRi)\n* Eligible for haploidentical hematopoietic stem cell transplantation\n* Availability of a suitable haploidentical donor\n* ECOG performance status 0-2\n* Adequate organ function:\n\n  * Left ventricular ejection fraction ≥50%\n  * Oxygen saturation \\>92% on room air\n  * Serum creatinine ≤1.5 × upper limit of normal (ULN)\n  * Total bilirubin ≤1.5 × ULN\n  * AST and ALT ≤2.0 × ULN\n  * DLCO ≥40% and FEV1 ≥50%\n* Ability to understand and sign informed consent\n\nExclusion Criteria:\n\n* Secondary AML (including AML evolving from myelodysplastic syndrome or therapy-related AML)\n* Active, uncontrolled infection\n* Severe uncontrolled systemic disease (e.g., unstable cardiovascular disease, recent stroke, or severe organ dysfunction)\n* HIV infection\n* Active hepatitis B or C requiring antiviral treatment\n* Pregnant or breastfeeding women\n* Known hypersensitivity to study drugs",{"count":346,"type":23},93,[59],"Acute myeloid leukemia (AML) is a serious blood cancer that mainly affects older adults. For patients who achieve their first complete remission (CR1), allogeneic hematopoietic stem cell transplantation (HSCT) may provide a chance for long-term survival. However, relapse after transplantation remains a major challenge.\n\nThis study aims to evaluate the effectiveness and safety of a conditioning regimen that combines thiotepa, busulfan, and fludarabine (TBF) before haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) in elderly patients with AML in first complete remission.\n\nEligible patients will receive the TBF conditioning regimen followed by stem cell transplantation from a partially matched donor. Participants will be followed to assess relapse-free survival, overall survival, transplant-related complications, and infections.\n\nThe results of this study may help improve treatment strategies and outcomes for elderly AML patients undergoing transplantation.",[350],"Acute Myeloid Leukemia",[352,353,354,355,356,357],"Haploidentical Stem Cell Transplantation","TBF Conditioning Regimen","Thiotepa Busulfan Fludarabine","Elderly AML","Allogeneic Hematopoietic Stem Cell Transplantation","Relapse-Free Survival","2026-04-26",{"date":360,"type":38},"2026-05-04",{"date":362,"type":23},"2026-06",{"date":364,"type":23},"2030-06",{"name":44,"class":45},{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":249,"enrollmentInfo":372,"targetDuration":4,"studyType":24,"phases":374,"briefSummary":375,"conditions":376,"keywords":378,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":386,"leadSponsor":388,"locationsCount":4},"100635800","phase-4-a-prospective-non-randomized-controlled-interventional-study-on-the-effect-of-shouhui-tongbian-capsules-combined-with-pancreatin-enteric-coated-capsules-on-pancreatic-exocrine-function-in-patients-after-curative-resection-for-pancreatic-cancer-100635800","NCT07557394","A Prospective Non-randomized Controlled Interventional Study on the Effect of Shouhui Tongbian Capsules Combined With Pancreatin Enteric-coated Capsules on Pancreatic Exocrine Function in Patients After Curative Resection for Pancreatic Cancer","Inclusion Criteria:\n\n1. Age: 18-80 years old;\n2. Pathologically confirmed pancreatic cancer and underwent pancreaticoduodenectomy(involved removing 50% of the pancreas, leaving 50% of the pancreas, ensuring balanced grouping);\n3. Presence of EPI symptoms (such as steatorrhea) and\u002For constipation (Bristol type 1-2, with \\\u003C3 bowel movements per week);\n4. Have informed consent and be proficient in using smartphone apps;\n5. Patients who are intended to receive treatment with either Daitong Capsules or Shouhui Tongbian Capsules, or both;\n6. The patient's condition is stable and suitable for participation in this study, as confirmed by investigator;\n7. Willing and able to follow the medication and follow-up plan specified in the study protocol, with an expected medication adherence rate of over 80%.\n\nExclusion Criteria:\n\n1. Allergic to pancreatic enzyme (porcine-derived protein allergy) or any ingredient of Shouhui Tongbian Capsules;\n2. Have a history of liver damage caused by Polygonum multiflorum;\n3. Combined with intestinal obstruction, severe hepatic and renal insufficiency (Child-Pugh Class C, eGFR \\\u003C 30 ml\u002Fmin), etc;\n4. Pregnant or lactating women;\n5. Psychological cognitive impairment.\n6. It is expected that the 12-weeks follow-up will not be completed.",{"count":373,"type":23},80,[26],"Exploratory evaluation comparing the addition of Shouhui Constipation Capsules to standard pancreatic enzyme therapy for improving exocrine pancreatic function in patients after pancreaticoduodenectomy.",[377],"Pancreatic Cancer",[379,380,381],"pancreaticoduodenectomy","PD","Pancreatic exocrine function","2026-04-22",{"date":384,"type":38},"2026-04-29",{"date":288,"type":23},{"date":387,"type":23},"2028-04-30",{"name":44,"class":45},{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":55,"enrollmentInfo":396,"targetDuration":4,"studyType":24,"phases":398,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":125},"100611929","antibiotic-prophylaxis-for-ureteroscopy-with-a-negative-pressure-suction-sheath-100611929","NCT07246967","Antibiotic Prophylaxis for Ureteroscopy With a Negative Pressure Suction Sheath","An International Multicenter Study on the Antimicrobial Prophylaxis Strategy for Flexible Ureteroscopic Lithotripsy Combined With a Flexible Negative Pressure Suction Sheath","Inclusion Criteria:\n\n1. Age 18-75 years.\n2. Diagnosed by CT with renal and\u002For upper ureteral stones, with the longest stone diameter being ≤2cm.\n3. Scheduled to undergo fURS lithotripsy.\n4. No preoperative symptoms of infection such as chills and fever, and the most recent preoperative urine culture is negative.\n5. No immunosuppressive status and no urinary flow obstruction caused by anatomical abnormalities.\n6. No use of long-acting antimicrobial agents within 7 days prior to surgery, and no use of intermediate or short-acting antimicrobial agents within 72 hours prior to surgery.\n7. Has signed and dated an informed consent form, indicating that the patient or their legal representative has been fully informed about the study-related information and has agreed to participate.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. Allergy to the investigational drug(s).\n3. Participation in other clinical trials within 30 days.\n4. Presence of other active infection foci requiring antimicrobial treatment.\n5. Concomitant severe systemic diseases, such as cardiac or pulmonary disease, malignant tumors, and immunodeficiency states.\n6. Congenital malformations of the urinary tract.\n7. History of kidney transplantation or urinary diversion surgery.\n8. Unable to provide samples or complete follow-up according to the study protocol.\n9. Unable to provide informed consent.\n10. Inability to achieve complete placement of the flexible negative-pressure suction sheath.\n11. Any other conditions that the investigator deems unsuitable for participation in this study.\n12. History of diabetes mellitus, immunocompromised.\n13. Renal insufficiency, neurogenic bladder.\n14. Recent preoperative history of stone-related fever.\n15. Long-term indwelling urinary drainage tube.\n16. Urine white blood cells \\>5\u002FHPF (High Power Field) or positive for urine nitrites.\n17. Large stone burden (e.g., staghorn calculus) or moderate to severe hydronephrosis.\n18. Imaging findings showing turbid urine in the renal pelvis where pyonephrosis or infectious stones cannot be excluded.",{"count":397,"type":23},500,[59],"This study, as a prospective, randomized, controlled, non-inferiority, international multicenter clinical trial, aims to evaluate whether a strategy of no antimicrobial prophylaxis is non-inferior to the traditional single-dose prophylaxis regimen in patients with a low risk of infection undergoing single-use flexible ureteroscopic lithotripsy combined with a flexible negative-pressure suction sheath. It is anticipated that this will have a substantial impact on infection prevention strategies in urological surgery.",[401,402],"Urolithiasis","Antibiotics",{"date":404,"type":38},"2026-04-23",{"date":406,"type":38},"2026-02-01",{"date":408,"type":23},"2027-12",{"name":44,"class":45},{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":18,"minAge":417,"maxAge":55,"enrollmentInfo":418,"targetDuration":4,"studyType":24,"phases":420,"briefSummary":422,"conditions":423,"keywords":426,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":125},"100629007","phase-3-vah-vs-va-in-newly-diagnosed-elderly-aml-100629007","NCT07469046","VAH vs VA in Newly Diagnosed Elderly AML","Venetoclax, Azacitidine Combined With Homoharringtonine Versus Venetoclax and Azacitidine in Newly Diagnosed Elderly (60-75 Years) Acute Myeloid Leukemia: A Multicenter, Open-label, Randomized, Controlled Clinical Trial","Inclusion Criteria:\n\n* Diagnosis of acute myeloid leukemia (AML), non-APL, according to the 2022 International Consensus Classification (ICC) criteria.\n* Age 60 to 75 years, inclusive.\n* Life expectancy of at least 12 weeks.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 3.\n* Adequate organ function unless abnormalities are considered due to leukemic organ involvement:\n\nSerum creatinine ≤ 1.5 × upper limit of normal (ULN). Oxygen saturation \\> 92% on room air. Total bilirubin ≤ 3.0 × ULN. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0 × ULN.\n\nIf laboratory abnormalities are considered due to leukemic organ involvement, total bilirubin ≤ 5.0 × ULN and ALT\u002FAST ≤ 5.0 × ULN are permitted.\n\n* Female subjects of childbearing potential must be postmenopausal or surgically sterile. Male subjects must agree to use effective contraception or abstain from sperm donation from study start through 90 days after the last dose of study treatment.\n* Ability to understand and voluntarily sign an informed consent form prior to any study-related procedures.\n\nExclusion Criteria:\n\n* Prior treatment with hypomethylating agents for myelodysplastic syndrome (MDS). Prior chemotherapy for AML, except hydroxyurea. Prior CAR-T cell therapy.\n* Prior investigational therapy for AML.\n* Documented history of myeloproliferative neoplasm (MPN).\n* Favorable-risk AML according to 2022 European LeukemiaNet (ELN) criteria.\n* Known active central nervous system (CNS) involvement of AML.\n* Known human immunodeficiency virus (HIV) infection.\n* Active hepatitis B or hepatitis C requiring antiviral therapy. Risk of hepatitis B reactivation (hepatitis B surface antigen positive or hepatitis B core antibody positive without antiviral prophylaxis).\n* History of another malignancy within 5 years prior to screening, except adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer treated with curative intent, or ductal carcinoma in situ treated with curative intent.\n* Unstable systemic disease including unstable angina, cerebrovascular accident, or transient ischemic attack within 3 months prior to screening. Myocardial infarction within 3 months prior to screening. Congestive heart failure New York Heart Association class III or IV. Recent pacemaker implantation. Severe liver, kidney, or metabolic disease requiring ongoing treatment. Pulmonary arterial hypertension. Clinically significant or uncontrolled arrhythmias including persistent atrial fibrillation or flutter, symptomatic ventricular arrhythmias, QTc ≥ 470 ms in males or ≥ 480 ms in females, second- or third-degree atrioventricular block without pacemaker, or arrhythmias requiring continuous antiarrhythmic therapy.\n* Malabsorption syndrome or any condition preventing enteral drug administration. Active systemic infection requiring treatment.\n* Significant neurological or psychiatric disorders requiring treatment including epilepsy grade 2 or higher, paralysis, aphasia, recent cerebral infarction, severe traumatic brain injury, dementia, Parkinson's disease, or schizophrenia.\n* Fertile males or females of childbearing potential unwilling to use effective contraception during treatment and for 12 months after completion of treatment.\n* White blood cell count \\> 25 × 10⁹\u002FL at screening (hydroxyurea permitted to reduce count to meet eligibility).","60 Years",{"count":419,"type":23},308,[421],"PHASE3","This is a multicenter, open-label, randomized, controlled phase III clinical trial designed to evaluate the efficacy and safety of the combination of Venetoclax, Azacitidine, and Homoharringtonine (VAH) compared to Venetoclax and Azacitidine (VA) alone in newly diagnosed elderly patients with Acute Myeloid Leukemia (AML).\n\nA total of 308 treatment-naïve patients aged 60-75 years with AML (non-APL) will be enrolled and randomly assigned in a 1:1 ratio to either the control arm (VA) or the experimental arm (VAH). The study aims to determine if the addition of Homoharringtonine to the standard VA regimen can improve response rates. To mitigate bias in this open-label study, the primary and key secondary efficacy endpoints will be assessed by an Independent Review Committee or central laboratory blinded to treatment allocation.",[424,425],"Acute Myeloid Leukemia (AML)","Elderly Patients (60-75 Years)",[424,427],"Elderly Patients","2026-04-06",{"date":143,"type":38},{"date":431,"type":23},"2026-04-10",{"date":433,"type":23},"2029-03-31",{"name":44,"class":45},{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":441,"minAge":54,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":24,"phases":444,"briefSummary":445,"conditions":446,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":125},"100580090","phase-2-exploration-of-treatment-effect-of-novel-hormone-therapy-combined-with-local-treatment-based-on-psma-petct-evaluation-in-mhscp-patients-100580090","NCT06832774","Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET\u002FCT Evaluation in mHSCP Patients","Inclusion Criteria:\n\n1. Male patients over the age of 18;\n2. The physical condition (PS) score of the Eastern Cooperative Oncology Group (ECOG) is 0, 1, or 2 points;\n3. Expected lifespan \\>2 years;\n4. All newly diagnosed patients with metastatic prostate cancer (mHSPC, metastatic hormone sensitive prostate cancer) diagnosed by PSMA PET\u002FCT, and still present active lesions on PSMA PET\u002FCT after receiving new endocrine therapy;\n5. Has not received any other treatment for prostate cancer before;\n6. No significant organ dysfunction upon evaluation;\n7. Agreed to sign the written consent form for this study, indicating a comprehensive understanding of the purpose and process of this study, and willingness to participate in this study.\n\nExclusion Criteria:\n\n1. A medical history of any other active malignant tumor within 2 years (excluding fully treated basal cell or squamous cell skin cancer, superficial bladder cancer or any other cancer in situ that is currently in complete remission);\n2. Prostate biopsy shows sarcomatoid cells, ductal carcinoma, or neuroendocrine cell components;\n3. Severe complications, immune suppression, severe mental illness, severe activity restriction, or inability to comply with this study;\n4. Currently participating in other clinical trials for prostate cancer;\n5. According to the researcher's judgment, there are conditions that are not in line with the best interests of the subjects participating in the study, or may hinder, limit, or interfere with the study protocol.","MALE",{"count":443,"type":23},192,[227],"At present, there is still controversy over the treatment of metastatic hormone sensitive prostate cancer (mHSPC). Major guidelines and consensus suggest that novel hormone therapy (NHT) should be used as the basic treatment for mHSPC, and metastasis directed therapy can be combined depending on the clinical situation. However, it is still unclear how to develop more specific and individualized treatment plans for mHSPC patients. On the other hand, prostate-specific membrane antigen (PSMA) which is highly specifically expressed in prostate epithelial cells has been widely used as a PET\u002FCT target for the diagnosis and staging of prostate cancer. However, there is still a lack of clinical evidence on how to use it to guide the treatment of prostate cancer. Therefore, this study intends to include patients diagnosed with mHSPC by PSMA PET\u002FCT. The patients received no prior treatment for prostate cancer or ADT plus NHT therapy only. After 8 months of ADT plus NHT, PSMA PET\u002FCT will be re-evaluated and patients with remaining active lesions on PSMA PET\u002FCT will be included for randomization. The aim of this study is to explore the effect of NHT combined with local treatment on delaying disease progression and prolonging survival in patients with active lesions on PSMA PET\u002FCT after NHT, providing new insights into the treatment of mHSCP patients.",[447],"Prostate Cancer Metastatic Disease","2026-03-20",{"date":450,"type":38},"2026-03-25",{"date":452,"type":38},"2025-08-01",{"date":454,"type":23},"2028-12-31",{"name":44,"class":45},{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":318,"enrollmentInfo":463,"targetDuration":4,"studyType":24,"phases":465,"briefSummary":466,"conditions":467,"keywords":469,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":125},"100620113","early-phase-1-early-phase-study-of-art002g1-injection-in-hefh-safety-tolerability-and-preliminary-efficacy-100620113","NCT07353398","Early-phase Study of ART002g1 Injection in HeFH: Safety, Tolerability and Preliminary Efficacy","Early-phase Clinical Study on Safety, Tolerability and Preliminary Efficacy of ART002g1 Injection in the Treatment of Heterozygous Familial Hypercholesterolemia","Subjects must meet all the following criteria to be eligible for enrollment:\n\n1. Male or female, aged 18 to 70 years (inclusive) at the time of signing the Informed Consent Form (ICF);\n2. Body weight between 45 and 90 kg (inclusive) at screening;\n3. Definite diagnosis of heterozygous familial hypercholesterolemia (HeFH), meeting either of the following two criteria (1) or (2):\n\n（1) HeFH diagnosed to be caused by mutations in the LDLR, APOB, or PCSK9 gene;\n\n(2) Meeting 2 out of the 3 following criteria for adults per the Dutch Lipid Clinical Network (DLCN) criteria:\n\n1. Serum LDL-C ≥ 4.7 mmol\u002FL without prior lipid-lowering treatment;\n2. Cutaneous or tendinous xanthomas, or arcus cornealis (in subjects \\\u003C 45 years old);\n3. Presence of FH or early-onset atherosclerotic cardiovascular disease (ASCVD) in first-degree relatives.\n\nSubjects must not be enrolled if they meet any one or more of the following exclusion criteria:\n\n1. Diagnosis of compound heterozygous FH, double heterozygous FH, or homozygous FH (HoFH);\n2. Positive for hepatitis B surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA titer ≥ 1 × 10² copies\u002FL; positive for hepatitis C virus (HCV) antibody with positive peripheral blood HCV RNA; positive for human immunodeficiency virus (HIV) antibody;\n3. Any unstable systemic disease, including but not limited to: unstable angina; cerebrovascular accident or transient ischemic attack (within 6 months prior to screening); myocardial infarction (within 6 months prior to screening); history of heart failure (NYHA Class II-IV); severe arrhythmia requiring pharmacotherapy; liver, kidney, or metabolic diseases; or other unstable systemic diseases as determined by the investigator;\n4. History of percutaneous transluminal coronary angioplasty (PTCA), percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG) within 6 months prior to the first dose; or documented severe coronary artery stenosis as confirmed by coronary CT or coronary angiography within 90 days prior to randomization.",{"count":464,"type":23},24,[136],"This study is an open-label, single ascending dose (SAD) study designed to evaluate the safety and tolerability of ART002g1 in patients with heterozygous familial hypercholesterolemia (HeFH) who require further reduction in low-density lipoprotein cholesterol (LDL-C). ART002g1 uses base editing technology, which is designed to interfere with the expression of the PCSK9 gene in the liver, thereby reducing the circulating levels of PCSK9 and LDL-C. The primary objectives of this study are to determine the safety and pharmacodynamic (PD) profiles of ART002g1 in this patient population.",[468],"Heterozygous Familial Hypercholesterolemia",[470,471,472],"ART002g1","LNP","HeFH","2026-03-15",{"date":475,"type":38},"2026-03-17",{"date":477,"type":23},"2026-03-11",{"date":479,"type":23},"2027-07",{"name":44,"class":45},{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":318,"enrollmentInfo":488,"targetDuration":4,"studyType":203,"phases":4,"briefSummary":490,"conditions":491,"keywords":493,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":125},"100629155","t-cell-lymphoma--stratified-therapy-after-response-to-first-line-treatment-nr-100629155","NCT07470996","T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR","T-START-NR","Inclusion Criteria:\n\n1. At the time of ICF signing, the subject must be 18-70 years of age, inclusive, regardless of gender.\n2. The subject must have achieved Stable Disease (SD) or Progressive Disease (PD) as assessed per the Lugano 2014 classification criteria after first-line systemic standard therapy (CHOP or a CHOP-like regimen). This includes subjects who failed to achieve a response after at least 4 cycles of standard chemotherapy or who experienced disease progression during treatment.\n3. The subject must have a histologically confirmed diagnosis of PTCL according to the 2016 revised WHO classification of lymphoid neoplasms (Swerdlow SH et al. 2016). Eligible histological subtypes are restricted to the following: Not Otherwise Specified (PTCL-NOS); ALK-negative Anaplastic Large Cell Lymphoma (ALK- ALCL); Follicular Helper T-cell Lymphoma or PTCL with a TFH phenotype (FTCL or PTCL-TFH). Additionally, they must meet the following condition:\n\n   Patients scheduled for allogeneic hematopoietic stem cell transplantation must have a suitable stem cell donor:\n\n   i. Related donors must be at least 5\u002F10 matched at HLA-A, -B, -C, -DQB1, and -DRB1.\n\n   ii. Unrelated donors must be at least 8\u002F10 matched at HLA-A, -B, -C, -DQB1, and -DRB1.\n4. Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) score ≤ 2.\n5. ECOG Performance Status score of 0 or 1, with no deterioration over the preceding two weeks.\n6. Life expectancy of at least 12 weeks.\n7. Adequate hepatic, renal, cardiac, and pulmonary function, defined as:\n\n   i. Hepatic: Serum total bilirubin ≤ 2 × ULN (or ≤ 3.0 × ULN in cases of Gilbert's syndrome or documented baseline liver involvement); Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤ 2.5 × ULN (or ≤ 5.0 × ULN in cases of liver involvement).\n\n   ii. Renal: Serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 50 mL\u002Fmin as calculated by the Cockcroft-Gault formula or measured.\n\n   iii. Cardiac: Left Ventricular Ejection Fraction (LVEF) ≥ 50% as measured by Multigated Acquisition (MUGA) scan or Echocardiography (ECHO).\n\n   iv. Baseline oxygen saturation on room air \\> 92%. v. Pulmonary: Diffusing capacity of the lungs for carbon monoxide (DLCO), corrected for hemoglobin, ≥ 40% and Forced Expiratory Volume in 1 second (FEV1) ≥ 50% of predicted.\n8. Voluntary participation in the clinical study; full understanding and awareness of the study and having signed the ICF; willingness and ability to comply with and complete all trial procedures.\n\nExclusion Criteria:\n\n1. Ann Arbor Stage I disease.\n2. History of any other malignancy within the past 5 years, except for locally cured malignancies after radical therapy (e.g., basal cell or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast).\n3. Active infection, including:\n\n   * Known active or latent tuberculosis, indicated by a positive tuberculin (PPD) skin test (defined as induration \\>10 mm or per local clinical criteria) or radiographic findings on chest X-ray\u002FCT suggestive of active\u002Flatent TB.\n\n     * Known history of Human Immunodeficiency Virus (HIV) infection and\u002For Acquired Immunodeficiency Syndrome (AIDS).\n\n       * Chronic active hepatitis B or C infection:\n\n         1. Hepatitis B virus (HBV) DNA-positive subjects are excluded; those with undetectable HBV-DNA are eligible. The upper limit of normal (ULN) for HBV-DNA is as defined by each participating center.\n         2. Hepatitis C virus (HCV) RNA-positive subjects are excluded; those with undetectable HCV-RNA are eligible. The ULN for HCV-RNA is as defined by each participating center.\n\n            * Active viral infections other than hepatitis B or C (e.g., herpes zoster, cytomegalovirus).\n\n              * Infection requiring intravenous antimicrobial therapy, evidenced by: hemodynamic instability related to infection, worsening or new infectious symptoms\u002Fsigns, new infectious foci on imaging, or persistent fever without localizing signs where infection cannot be ruled out.\n\n                * Positive serum DNA test for Epstein-Barr virus (EBV).\n4. Poorly controlled cardiac symptoms or diseases, including:\n\n   i. Heart failure \\> New York Heart Association (NYHA) Class II. ii. Unstable angina. iii. Myocardial infarction within the past year. iv. Clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention.\n5. Pregnant or lactating women, and subjects of childbearing potential unwilling to use effective contraception.\n6. Patients with psychiatric disorders or those unable to provide informed consent.\n7. PTCL patients with central nervous system involvement.\n8. PTCL patients who have received prior PD-1\u002FPD-L1 inhibitor therapy.\n9. Any other condition that, in the investigator's judgment, renders the subject unsuitable for study participation.",{"count":489,"type":23},58,"This study is a multicenter, two-arm, prospective clinical trial, comprising two groups: the allogeneic hematopoietic stem cell transplantation group (Allo-HSCT) and the alternative salvage regimens. It aims to evaluate the efficacy and safety of Allo-HSCT and alternative salvage regimens in the treatment of peripheral T-cell lymphoma that has achieved no response (NR) after first-line therapy. During the screening\u002Fbaseline period, informed consent will be obtained, and inclusion\u002Fexclusion criteria will be verified. Group assignment (Allo-HSCT vs. alternative salvage regimens) will be determined taking into account the availability of a matched donor and the patient's preference. The study plans to enroll 29 patients in each group. Data on demographics and medical history will be collected, and assessments including vital signs, physical examination, PET-CT, bone marrow aspiration smear, flow cytometry, and bone marrow pathology will be performed.",[492],"Peripheral T Cell Lymphoma",[492,494,495,496],"no response","allogeneic hematopoietic stem cell transplantation","alternative salvage regimens","2026-03-10",{"date":499,"type":38},"2026-03-13",{"date":501,"type":38},"2025-10-01",{"date":503,"type":23},"2029-09-30",{"name":44,"class":45},{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":24,"phases":513,"briefSummary":514,"conditions":515,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":73},"100620846","early-phase-1-safety-and-efficacy-evaluation-of-lx111-gene-therapy-in-dme-patients-100620846","NCT07362927","Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients","An Exploratory Clinical Study Evaluating LX111 Gene Therapy in Patients With Diabetic Macular Edema (DME)","Inclusion Criteria:\n\n1. Willing to sign the informed consent, and willing to attend follow-up visits;\n2. Age ≥ 18;\n3. Type I or Type II diabetes mellitus with macular thickening secondary to DME involving the center of the fovea;\n4. CST ≥ 300 μm in the study eye at Screening;\n5. BCVA ETDRS letters between 19 and 73;\n6. Participants must have received anti-VEGF therapy within 12 months prior to screening and demonstrated a meaningful response;\n7. Male subjects whose partner is a fertile female or female subjects who are fertile, agree to take effective contraceptive measures from the screening period until the last follow-up.\n\nExclusion Criteria:\n\n1. Active proliferative diabetic retinopathy (PDR);\n2. Presence of iris neovascularization in the study eye at Screening;\n3. Retinal laser photocoagulation in the study eye within 3 months prior to Screening;\n4. Prior gene therapy in the study eye;\n5. The study eye has been treated with an intravitreal dexamethasone implant (Ozurdex®) within 6 months prior to Screening.\n6. Systemic anti-VEGF treatment within 3 months before Screening;\n7. Received an investigational drug, agent, device, or therapy (ocular or non-ocular) in the 3 months (or at least 5 half-lives, whichever is longer) prior to Screening;",{"count":107,"type":23},[136],"The goal of this study is to evaluate the safety and efficacy of LX111 treatment of DME. This study will enroll participants aged ≥ 18 vears old to receive a single unilateral intravitreal (lVT) injection of LX111 to evaluate its safety and efficacy.",[516],"Diabetic Macular Edema (DME)","2026-03-09",{"date":497,"type":38},{"date":520,"type":23},"2026-03",{"date":522,"type":23},"2031-09",{"name":44,"class":45},{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":18,"minAge":104,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":24,"phases":532,"briefSummary":533,"conditions":534,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":536,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":125},"100597043","early-phase-1-safety-and-efficacy-evaluation-of-lx111-gene-therapy-in-namd-patients-100597043","NCT07053358","Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients","An Exploratory Clinical Study Evaluating LX111 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD)","Inclusion Criteria:\n\n1. Willing to sign the informed consent, and willing to attend follow-up visits.\n2. Age ≥ 50\n3. Diagnosis of active CNV secondary to neovascular AMD\n4. BCVA ETDRS letters between 5 and 63\n5. Subjects must have received a minimum of 2 injections within 6 months prior to screening and demonstrated a meaningful response to anti-VEGF therapy\n6. Male subjects whose partner is a fertile female or female subjects who are fertile, agree to take effective contraceptive measures from the screening period until the last follow-up.\n\nExclusion Criteria:\n\n1. CNV or macular edema in the study eye secondary to diseases other than nAMD\n2. Retinal detachment, uveitis, uncontrolled glaucoma in the study eye, or any condition preventing visual acuity improvement\n3. Acute coronary syndrome, myocardial infarction or coronary artery revascularization, CVA, TIA in the last 6 months\n4. Uncontrolled hypertension defined as average SBP ≥160 mmHg or an average DBP ≥100 mmHg\n5. Uncontrolled diabetes defined as HbA1c \\>8.0% within 28 days prior to screening",{"count":134,"type":23},[136],"The goal of this study is to evaluate the safety and efficacy of LX111 treatment of nAMD. This study will enroll subjects aged ≥ 50 vears old to receive a single unilateral intravitreal (lVT) injection of LX111 to evaluate its safety and efficacy.",[535],"Neovascular Age-related Macular Degeneration",{"date":497,"type":38},{"date":538,"type":38},"2025-07-02",{"date":540,"type":23},"2029-12-30",{"name":44,"class":45},{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":4,"eligibilityCriteria":548,"healthyVolunteers":12,"sex":18,"minAge":549,"maxAge":4,"enrollmentInfo":550,"targetDuration":4,"studyType":24,"phases":552,"briefSummary":553,"conditions":554,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":556,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":125},"100597787","early-phase-1-a-study-of-lx107-gene-therapy-in-aipl1-ird-patients-100597787","NCT07063030","A Study of LX107 Gene Therapy in AIPL1-IRD Patients","An Exploratory Clinical Study to Evaluate LX107 Gene Therapy in Patients With AIPL1 Biallelic Mutation-related Inherited Retinal Dystrophy (AIPL1-IRD)","Inclusion Criteria:\n\n1. The subject and\u002For their guardian signs a written informed consent form and is willing to comply with the long-term follow-up protocol and supporting protocols.\n2. Adult or pediatric patients (aged ≥ 4 years) diagnosed with AIPL1-IRD.\n3. Definitive molecular diagnosis of biallelic AIPL1 gene mutations confirmed by next-generation sequencing combined with Sanger validation.\n4. The study eye has a best-corrected visual acuity of no more than 58 letters (approximately equivalent to decimal visual acuity ≤ 0.3) using the ETDRS visual acuity chart at baseline.\n\nNote: Only one eye will be designated as the \"study eye\" (i.e., the eye to receive treatment) at the investigator's discretion.\n\nExclusion Criteria:For any eye with the following conditions:\n\n1. A history of ocular diseases that, in the investigator's judgment, may hinder the planned treatment or interfere with the interpretation of study endpoints (e.g., glaucoma, diabetic retinopathy, retinal vein occlusion, retinal detachment, posterior or panuveitis, etc.).\n2. Any eye with a history of gene therapy for IRD or other hereditary neuro-ophthalmic diseases (including but not limited to other viral vector-based gene therapies, mRNA therapies, etc.).\n3. A lack of sufficient viable retinal cells as determined by non-invasive methods such as OCT or ophthalmoscopy.\n4. Any active intraocular or periocular infection in the study eye (e.g., infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis, uveitis).\n5. A history of intraocular surgery (e.g., vitrectomy, cataract surgery, trabeculectomy, or other filtering surgery) in the 6 months prior to the screening visit.\n\n   For any systemic conditions:\n6. Uncontrolled hypertension, defined as systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg. If the initial measurement exceeds the above limits, it may be repeated on the same day or another day during the screening period; if the subject is taking oral antihypertensive drugs, they must have been on a stable dose of the same drug for at least 30 days prior to screening.\n7. Diabetic patients meeting any of the following criteria: ① known to have macrovascular complications; ② baseline HbA1c \\> 7.5%; ③ receiving treatment with two or more oral hypoglycemic agents, insulin, or GLP-1 receptor agonists.\n8. A history of any other diseases, metabolic disorders, physical examination findings, or clinical laboratory abnormalities that, in the investigator's judgment, may contraindicate the use of the study drug, interfere with the interpretation of study results, or place the subject at high risk of treatment complications, including but not limited to: AIDS, syphilis, acute\u002Fchronic active hepatitis B or C, coagulation disorders, a history of treated or untreated malignancy within the past 5 years (except for localized basal cell carcinoma of the skin or in situ cervical cancer), etc.\n9. Any of the following laboratory abnormalities: ① platelet count \\\u003C 100 × 10⁹\u002FL, hemoglobin (Hb) \\\u003C 10 g\u002FdL (males) or \\\u003C 9 g\u002FdL (females); ② aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 3 × ULN; ③ serum creatinine or urea \\> 1.5 × ULN.\n10. Administration of any other investigational drug (except vitamins and minerals) within 3 months prior to screening, or an attempt to participate in another clinical trial during the study period.\n11. Other circumstances deemed unsuitable for enrollment by the investigator.\n12. Unwillingness to use effective contraceptive methods during the study; pregnant or lactating women, or women planning to become pregnant or lactate during the study period.","4 Years",{"count":551,"type":23},13,[136],"Administering subretinal injection of LX107 injection (a gene therapy drug) to patients with retinal dystrophy caused by AIPL1 gene mutation to evaluate its efficacy and safety.",[555],"Retinal Dystrophy",{"date":497,"type":38},{"date":558,"type":38},"2025-07-15",{"date":560,"type":23},"2030-12-31",{"name":44,"class":45},{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":569,"enrollmentInfo":570,"targetDuration":4,"studyType":24,"phases":572,"briefSummary":573,"conditions":574,"keywords":576,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":584,"completionDateStruct":585,"leadSponsor":587,"locationsCount":125},"100628567","phase-2-6-vs-3-cycles-of-neoadjuvant-chemotherapy-for-potentially-resectable-locally-advanced-thymic-epithelial-tumors-100628567","NCT07463313","6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors","A Randomized Controlled Trial of 6 Versus 3 Cycles of Neoadjuvant Chemotherapy on Event-Free Survival in Patients With Potentially Resectable Locally Advanced Thymic Epithelial Tumors","Inclusion Criteria:\n\n* Histologically or cytologically confirmed thymic epithelial tumor (thymoma or thymic carcinoma)\n* Locally advanced, potentially resectable disease (Masaoka-Koga stage III or IVA), as evaluated by a multidisciplinary team (MDT) including thoracic surgery and thoracic oncology\n* Age 18 to 65 years\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Adequate bone marrow function: absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL, platelet count ≥100×10⁹\u002FL, hemoglobin ≥90 g\u002FL\n* Adequate liver function: total bilirubin ≤1.5× upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN\n* Adequate renal function: creatinine clearance ≥50 mL\u002Fmin (Cockcroft-Gault formula)\n* No prior systemic anticancer therapy for thymic epithelial tumor\n* At least one measurable lesion per RECIST v1.1\n* Willing to accept randomization and able to comply with study procedures\n* Written informed consent obtained prior to any study-related procedures\n\nExclusion Criteria:\n\n* Prior chemotherapy, targeted therapy, or immunotherapy for thymic epithelial tumor\n* Prior thoracic radiation therapy\n* Active autoimmune disease requiring systemic treatment within the past 2 years\n* Known hypersensitivity or contraindication to study drugs (cisplatin, epirubicin, etoposide, ifosfamide, or any component of these formulations)\n* Severe cardiac dysfunction: New York Heart Association (NYHA) class III or IV heart failure, or left ventricular ejection fraction (LVEF) \\\u003C50%\n* Active hepatitis B (HBsAg positive with HBV DNA ≥2000 IU\u002FmL), active hepatitis C, or known HIV infection\n* Pregnancy or lactation; women of childbearing potential unwilling to use adequate contraception\n* Other malignancy within 5 years prior to enrollment, except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix\n* Uncontrolled active infection requiring systemic therapy\n* Any condition that, in the investigator's judgment, would preclude safe participation in the study","65 Years",{"count":571,"type":23},116,[227,421],"This randomized controlled trial compares 6 versus 3 cycles of neoadjuvant chemotherapy in patients with potentially resectable locally advanced thymic epithelial tumors (TETs, WHO type AB\u002FB\u002FC, AJCC TNM stage IIIA-IVA). Patients are randomized 1:1 to receive either 6 or 3 cycles of chemotherapy (cisplatin + doxorubicin + cyclophosphamide for type B; nab-paclitaxel + carboplatin for type C thymoma\u002Fthymic carcinoma) every 3 weeks, followed by surgical resection when feasible. The primary endpoint is event-free survival (EFS). The study aims to determine whether extended neoadjuvant chemotherapy improves surgical outcomes and long-term survival in this rare malignancy.",[575],"Thymoma and Thymic Carcinoma",[577,578,579,580,581],"Neoadjuvant Chemotherapy","Thymic Epithelial Tumor","Thymic Carcinoma","Event-Free Survival","Mediastinal Tumor","2026-03-06",{"date":477,"type":38},{"date":520,"type":23},{"date":586,"type":23},"2032-03",{"name":44,"class":45},{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":593,"acronym":4,"eligibilityCriteria":594,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":298,"enrollmentInfo":595,"targetDuration":4,"studyType":24,"phases":597,"briefSummary":598,"conditions":599,"keywords":600,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":125},"100553270","phase-2-venetoclax-and-azacitidine-combined-with-homoharringtonine-followed-by-allo-hsct-for-intermediate-and-high-risk-aml-100553270","NCT06483906","Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.","Efficacy and Safety of Venetoclax and Azacitidine Combined With Low-Intensity Homoharringtonine Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate\u002FHigh-Risk Newly Diagnosed Acute Myeloid Leukemia","Inclusion Criteria:\n\n1. Age between 18 and 55 years, inclusive, regardless of gender.\n2. Diagnosed with AML (excluding APL) according to the 2022 International Consensus Classification (ICC) for AML \\[1\\].\n3. Evaluated as intermediate\u002Fhigh-risk AML based on the 2022 ELN AML guidelines (see Appendix 1).\n4. No prior treatment for acute leukemia, including hypomethylating agents used for leukemia or myelodysplastic syndromes (MDS), except for hydroxyurea.\n5. Patients must have a suitable hematopoietic stem cell donor.\n6. Hematopoietic cell transplantation comorbidity index (HCT-CI) score ≤ 2.\n7. ECOG (Eastern Cooperative Oncology Group) performance status: 0-2.\n8. Adequate liver, kidney, and cardiopulmonary function, meeting the following requirements:\n\n   1. Serum creatinine ≤ 1.5x ULN (the upper limit of normal);\n   2. Cardiac function: Ejection fraction ≥ 50%;\n   3. Baseline oxygen saturation \\> 92%;\n   4. Total bilirubin ≤ 1.5 x ULN; ALT and AST ≤ 2.0 x ULN;\n   5. Pulmonary function: DLCO (corrected for hemoglobin) ≥ 40% and FEV1 (Forced Expiratory Volume in 1 second) ≥ 50%.\n\n      9\\) Patients must have the ability to understand and be willing to participate in this study and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Acute promyelocytic leukemia.\n2. Presence of extramedullary disease manifestations at diagnosis or during treatment, including central nervous system involvement.\n3. History of malignancies other than myeloid neoplasms within the past 5 years prior to screening, except adequately treated cervical carcinoma in situ, basal cell carcinoma, squamous cell carcinoma of the skin, and localized prostate cancer after radical surgery, and ductal carcinoma in situ after radical surgery.\n\n4\\) ECOG \\> 2. 5) HCT-CI score ≥ 3. 6) Any unstable systemic diseases, including but not limited to unstable angina, recent cerebrovascular accidents or transient ischemic attacks within the 3 months prior to screening, myocardial infarction within the 3 months prior to screening, congestive heart failure (New York Heart Association \\[NYHA\\] class ≥ III), severe arrhythmias requiring drug treatment after pacemaker implantation, significant liver, kidney, or metabolic diseases, and pulmonary arterial hypertension.\n\n7\\) Active, uncontrolled infections, including those associated with hemodynamic instability, new or worsening infection symptoms or signs, new infectious lesions on imaging, or persistent unexplained fever without signs or symptoms of infection.\n\n8\\) Conditions requiring treatment such as grade 2 or higher seizures, paralysis, aphasia, recent severe cerebral infarction, severe traumatic brain injury, dementia, Parkinson's disease, or schizophrenia.\n\n9\\) HIV-infected individuals. 10) Active hepatitis B (HBV) or active hepatitis C (HCV) requiring antiviral therapy.\n\nPatients at risk of HBV reactivation, are defined as those who are positive for hepatitis B surface antigen or core antibody without receiving antiviral therapy.\n\n11\\) History of autoimmune diseases. 12) Pregnant or breastfeeding women. 13)Fertile males and females unwilling to use contraception during the treatment period and for 12 months after treatment.",{"count":596,"type":23},56,[227],"This study is a single-center, single-arm, prospective phase II clinical trial evaluating the efficacy and safety of the VAH (Venetoclax and Azacitidine combined with Homoharringtonine) regimen, followed by allo-HSCT for intermediate and high-risk AML. Eligible patients receive two cycles of the VAH chemotherapy regimen. If minimal residual disease (MRD) is negative after these two cycles, patients proceed to the transplantation process. If MRD remains positive, patients receive an additional two cycles of the VAH regimen. Upon achieving MRD negativity, they then proceed to the transplantation process.\n\nThe conditioning regimen includes fludarabine at 30 mg\u002Fm²\u002Fday from day -7 to day -3 (5 days), cytarabine at 1-1.5 g\u002Fm²\u002Fday from day -7 to day -3 (5 days), and busulfan at 3.2 mg\u002Fkg\u002Fday from day -5 to day -3 (3 days). Conditioning begins on day -6, and donor hematopoietic stem cell infusion is performed on day 0.\n\nAll patients will undergo bone marrow examination on day 14 and day 28 post-transplant, followed by bone marrow examinations every 30 days within the first year after transplantation, and every 60 days within the second year. If disease relapse is suspected during the follow-up period, bone marrow or extramedullary relapse site examinations will be conducted at any time.\n\nThe primary endpoint is the 1-year and 2-year overall survival (OS). Secondary endpoints include the complete response (CR) rate after 1 and 2 cycles of chemotherapy; 1-year and 2-year disease-free survival (DFS) following the achievement of CR through induction therapy; cumulative relapse rate; non-relapse mortality (NRM); incidence of acute graft-versus-host disease (GVHD) within 180 days post-transplant; and the cumulative incidence of chronic GVHD within 1 year and 2 years post-transplant.",[350],[350,495,601,602,603],"Venetoclax","Azacitidine","Homoharringtonine","2026-02-28",{"date":606,"type":38},"2026-03-03",{"date":608,"type":38},"2024-07-02",{"date":610,"type":23},"2028-07-01",{"name":44,"class":45},""]